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Abstract 
BACKGROUND: A variety of recent evidence exists about the clinical implication of low level of Pregnancy-
associated plasma protein A (PAPP-A) in pregnancy. This glycoprotein is a protease, which releases the Insulin-
like growth factor from IGFBP 4. Its role is a trophoblastic invasion of decidua, stimulation of cell mitosis and 
differentiation. It has an immunosuppressive effect in the placenta, inhibition of coagulation and complex role for 
integration of all these processes in the placenta. Level of PAPP-A (under 0.4 MoM-Multiple of Medians) in first-
trimester screening in chromosomally and morphologically normal fetuses, could influence fetal weight, 
preeclampsia, premature birth and stillbirth. As a result of the complications mentioned above, there is implication 
on timing, mode of delivery and condition of the newborn. 
AIM: The study aims to evaluate the influence of low PAPP-A, measured in the first trimester on the outcome of 
pregnancy, with accent disorders which are the result of placental insufficiency. Also, gestational week, mode of 
delivery and condition of newborn secondary underlying conditions will be evaluated. 
MATERIAL AND METHODS: After given information and consultation about the expectation from the screening, 
pregnant women with a singleton pregnancy were tested for First Trimester Screening to estimate the risk for 
Trisomy 21, 13, 18- the most frequent chromosomopathies. After exclusion of chromosomopathies and congenital 
malformations, one hundred and fourteen patients enrolled in the study. The target group (n = 64) with PAPP-A 
below 0.4 MoM and control group (n = 50) with PAPP-A equal and above 0.4 MoM. An assessment of mode and 
time of delivery and presence of small for gestational age newborns, preeclampsia, premature birth and newborn 
condition at delivery was made. 
RESULTS: The percentage of the patients delivered in term was similar between the target group (n = 64) and 
the control group (n = 50), 82.81% vs 82.0% respectively. The rate of cesarean section was 29.7 % in the target 
group vs 32% in the control group. A significant difference was found about elective vs urgent cesarean section in 
favour of the target group. The difference was present about the complication in pregnancy before delivery, 56% 
vs 22%, p = 0.023, which were the main indication for cesarean section. The difference in newborn outcome was 
not significant. 
CONCLUSION: There is a difference in frequency of complications, in the cases with PAPP-A under 0.4 MoM, 
such as premature birth, preeclampsia compound with SGA fetuses versus the control group. The difference for 
SGA newborn and premature birth among the groups has statistical significance. The patients delivered with 
cesarean section were with the main indications SGA or elevated blood pressure, often occurred combined with 
prematurity. Apgar score and birth weight were similar in target and control group, but the newborns with a birth 
weight under 2500 g. were more frequent in the target group. Because these results did not show another 
significance among two groups, probably lower cut-off is needed, combining with another test (Doppler of uterine 
arteries in the first trimester, biochemical test). Presence of other diseases which could hurt placental function 
should be emphasised. 
 
 
 
Introduction 
 
The measurement of Pregnancy-associated 
plasma protein A in the first trimester of pregnancy 
(PAPP-A), is a part of the combined screening in the 
first trimester for chromosomopathies, according to 
the recommendations of the Fetal Medicine 
Foundation (FMF) [1], [2]. Since its discovery by Lin in 
1974, till now, this glycoprotein remains a dilemma 
about the interpretation of its concentrations in 
placenta and blood in pregnant women during 
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pregnancy, in the first trimester and use in everyday 
practice [3]. PAPP-A is a large glycoprotein in 
complex with eosinophilic pro-Major basic protein 
(pro-MBP) [4]. It is a highly potent protease for insulin-
like growth factor binding protein 4 and 5 (IGFBP 4 
and 5). The protein is a powerful inhibitor of IGF in 
vitro, suggesting that proteolysis acts like a positive 
regulator of the IGF- availability. PAPP-A in the serum 
of the pregnant woman has an IGF- dependent 
protease activity on IGFBP-4 [5]. This protease has an 
important role in the local proliferative answer, acting 
by accelerating the cell division. It increases the 
bioavailability of IGF, which in return mediates the 
trophoblastic invasion of decidua and modulates the 
transport of glucose and amino acids in the placenta 
[4], [5], [6]. Thus, low PAPP -A might be a cause for 
inappropriate placental perfusion affecting the fetal 
growth and leading to placental depended on adverse 
conditions in pregnancy [7], [8]. PAPP-A is a placental 
product from syncytiotrophoblast and septal X cells, 
and its concentration is low in the first trimester. 
Insufficient syncytiotrophoblast development and 
function have an important role in the abnormal 
placental secretion of main placental proteins (beta 
HCG, PAPP-A, SP1 and HPL) [3], [4], [7], [9]. The 
median value for PAPP-A increase from 0.4 MoM in a 
10
th
 gestational week to approximately 0.7 MoM in the 
13
th
 gestational week, so the PAPP-A increases as 
the pregnancy progresses till term [7], [8], [9]. Does 
low value of PAPP-A (< 0.4 MoM) could predict an 
adverse perinatal outcome that includes fetuses with 
intrauterine growth restriction (IUGR) resulting in SGA 
infant in most of the cases, preeclampsia and preterm 
birth is still unclear [10], [11], [12], [13], [14], [15]. 
The study aims to evaluate the influence of 
low PAPP-A, measured in the first trimester on the 
outcome of pregnancy, with accent disorders which 
are the result of placental insufficiency. Also, 
gestational week, mode of delivery and condition of 
newborn secondary underlying conditions will be 
evaluated. 
 
 
Material and Methods 
 
This study was submitted and approved by 
the Ethical Review Committee of the Medical Faculty 
in Skopje and is in adherence to the laws and 
regulations of the country in which the research was 
conducted. Written consent with patient permission 
was obtained from each patient. A prospective 
longitudinal study was conducted at the University 
Clinic of Gynecology and Obstetrics, Skopje. Analyses 
for PAPP –A were performed at the Biochemical, 
clinical laboratory. chromosomopathies were excluded 
at Cytogenetic laboratory. The pregnant women were 
followed up during the pregnancy and delivered 2017 
and 2018. After First Trimester screening, if the risk 
was < 1:250, prenatal genetic testing to exclude 
chromosomopathies was offered. A total of 114 
patients without chromosomopathies and congenital 
malformations enrolled in the study. Depend on the 
level of PAPP-A; there were 64 patients in the target 
group with values of PAPP-A below of 0.4 MoM and 
50 patients in the control group with values of PAPP-A 
≥ 0.4 MoM. The data for the patients was collected by 
a questionnaire that included demographic 
information, information about the current pregnancy, 
personal and obstetric history. In both groups, the 
presence of obstetrical complications such as 
preeclampsia, small for gestational age, premature 
deliveries, fetal distress, mode of delivery and 
indications for caesarean section were evaluated. The 
definition of hypertensive disorders, small for 
gestational age and preterm delivery was by relevant 
obstetric guidelines. The newborn's condition at 
delivery was evaluated.  
The concentrations of free β HCG and PAPP-
A were measured from 5 ml of peripheral vein blood. 
The sample was taken with vacutainer in a test tube 
without anticoagulant. Siemens Healthinner Immulite 
2000 XPi device, with a method of 
chemiluminescence immunoassay, was used, and the 
risk was calculated (Siemens Corporation). 
 
Statistical method 
SPSS for Windows V.23.0 was used. Average 
and standard deviation were used for numeric 
variables with symmetrical distribution and median for 
numerical variables with asymmetrical distribution. 
Categorical parameters are presented with distribution 
of frequencies. Statistical significance among 
attributive parameters was determined with the Chi-
square test and independent numerical parameters 
with Student T-test and Mann-Whitney U test. 
The values of p < 0.05 were taken for 
statistically significant. The results are presented in 
absolute values and percentages.  
 
 
Results  
 
A total of 114 patients were enrolled. The 
patients were divided into two groups: target group-64 
patients and control- 50 patients.  
Maternal age - the average age in the target 
group was 28.8 ± 4.8 years and the control 30.6 ± 5.3 
years, p = 0.057 (Table 1). 
Table 1: Maternal age  
Group Descriptive Statistics P - level 
N Mean ± SD 
Maternal age 
Range 
Target group 64 28.8 ± 4.8 18– 41 P = 0.057 ns 
Control group 50 30.6 ± 5.3 17– 41  
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Gestational age of delivery was similar 
between two groups, p = 0.87 (Table 2). 
Table 2: Gestational week of delivery 
Group Descriptive statistics P - level 
N Mean ± sd Range 
Gestational week of delivery 
Target group 64 38.35 ± 2.6 30.5-41.5 T = 0.16 
Control group 50 38.42 ± 2.2 30.2-41.5 P = 0.87 
     
 
The mode of delivery – vaginal vs caesarean 
section wasn’t significantly different between the 
groups (p = 0.79). Delivery by caesarean section 
occurred in 29.7% target group vs 32% of the control 
group (Table 3). 
Table 3: Mode of delivery and type of indication  
Variable Group P - level 
N Target 
N (%) 
Control 
N (%) 
Mode of delivery 
Vaginal 79 45 (70.31) 34 (68) 
2 
= 0.07 
Cesarean section  35 19 (29.69) 16 (32) P = 0.79 
Type of indication for cesarean section 
Elective 13 8 (12.5) 5 (10) 
2 
= 0.44 
Urgent 22 11(17.19) 11(22) P = 0.51 
 
We didn’t find a difference between delivery 
by elective vs urgent caesarean section, (p = 0.51). 
The results show a significant difference in 
complications in pregnancy before delivery, among 
the groups (p = 0.023) (Table 4). 
Table 4: Complications before delivery  
Variable Group P - level 
N Target 
N (%) 
Control 
N (%) 
Complications before delivery 
Yes 38 27 (42.19) 11 (22) P = 0.023 sig 
No 76 37 (57.81) 39 (78)  
 
Distribution of complications is present in 
Table 5. The most frequent complications were 
premature birth and SGA newborn in the target group. 
Table 5: Distribution of complications 
Complication  
Before delivery 
Group 
N Target 
N 
Control 
N 
No 76 37 (57.81%) 39 (78 %) 
Yes 38 27 (42.19%) 11 (22%) 
Distribution of complications    
Premature delivery due to uterine contractions 11 3 8 
Sga 15 11 4 
Sga, pe 4 4 0 
Sga, fetal distress 1 1 0 
Pe, fetal distress 1 1 0 
Sga, pe, fetal distress 1 1 0 
Pe 6 4 2 
Fetal distress 1 1 0 
Stillbirth 1 1 0 
Abruption 1 1 0 
Lga 3 3 0 
Total number  45 31 14 
 
There are a discrepancy in the total number 
(n = 45) and patients with (noted as main) 
complications (n = 38) because more than one 
complication is present in the same patient. The 
frequency of SGA newborn has significant statistical 
difference p = 0.023 (Table 6). 
 
Table 6: Distribution of SGA newborn 
Sga Group P - level 
N Target 
N (%) 
Control 
N (%) 
Yes 21 17 (26.56) 4 (8) P = 0.023 sig 
No 93 47 (73.44) 46 (92)  
 
In the target group, the duration of pregnancy 
till 37 g. w. or less was significantly more frequent 
than in control-32.8% (21) vs.16% (8), p = 0.04 (Table 
7). 
Table 7: Duration of pregnancy (g. w.) 
Gestational week Group P - level 
N Target 
N (%) 
Control 
N (%) 
> 37 week 85 43 (67.19) 42 (84) P = 0.04 sig 
≤ 37 week 29 21 (32.81) 8 (16)  
 
 
Outcome of newborn  
Average birth weight was (in grams) 3028.9 ± 
743.4 vs. 3175.4 ± 677.9. p = 0.13 Very similar results 
were for birth height (in cm) 48.94 ± 3.1 vs. 49.36 ± 
3.5, p = 0.21. 
 
Viability of newborn  
The value of Apgar score in the first and fifth 
minute, didn’t show statistical significance (p = 0.43, p 
= 0.19) respectively, although they were lower in the 
target group at the fifth minute (Table 8). 
Table 8: Apgar score at first and fifth minute 
Apgar 
score 
Group Descriptive Statistics P = level 
N Mean ± SD Range Мedian 
First minute Target 64 7.68 ± 0.8 4 - 9 8 (8– 8) Z = 0.78 
 Control 50 7.82 ± 0.7 5 – 9 8 (8– 8) P = 0.43 ns 
Fifth minute Target 64 8.6 ± 0.8 6– 10 8 (8– 9) Z = 1.3 
 Control 50 8.82 ± 0.6 6– 10 9 (9– 9) P = 0.19 ns 
 
 
 
Discussion 
 
Level of PAPP-A (under 0.4 MoM) in first-
trimester screening in chromosomally and 
morphologically healthy fetuses, could contribute to 
the placental mediated complication, such as 
preeclampsia, premature birth, SGA, stillbirth, 
miscarriages [15], [16]. This implies on time and mode 
of delivery and newborn outcome. 
In the study, there were no significant 
differences in maternal age. The total premature 
deliveries were due to uterine contractions and 
iatrogenic termination because of complications in 
pregnancy. The frequency of pregnancy up to 37 g.w. 
in target group was higher with statistical significance 
(p = 0.04) [15], [17]. We didn’t find a difference for 
preeclampsia compare to other studies [16], [17]. 
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There are studies for positive association between 
complications and low level of PAPP-A under 0.3 
MoM [12], [13], [18], [19].  
In our study urgent cesarean sections rate is 
almost 20% and is similar in both groups. Other 
studies present higher once in target group-30% [14]. 
Preeclampsia was present around 10% in the 
target group, similar to unselected pregnant women 
(6-8%). Almost 17% of a newborn in the target group 
were small for gestational age below the 10
th
 
percentile, higher than in Thompson study-7.44% [20].
 
Some studies show a significant difference in 
an adverse outcome in a group with PAPP-A below 
0.4 MoM, probably because of different statistical 
power [21], [22]. 
There are a lot of studies with a different 
outcome. They included patients with different 
characteristics (race origin, body weight, previous 
poor obstetric history). Also, the presence of 
underlying disorders such as hypertension, diabetes, 
hypothyreosis, autoimmune disease etc. was 
included. In our study, the patients didn’t have these 
conditions as they were exclusion criteria in the study. 
The number of patients enrolled in the studies is 
different; from national level study to trial study. Our 
study was with a relatively lower number of patients 
according to other studies. Better predictive results 
have studies which involve other tests (doppler of 
uterine arteries and fetal dopplers, different 
biochemical tests) [21], [23], [24]. 
In conclusion, there is a difference in 
unfavourable outcome in the cases with PAPP-A 
under 0.4 MoM, particular in the group of patients with 
premature birth, and SGA as a result of placental 
insufficiency. These factors lead to fetal distress or 
compromised fetal oxygenation. The patients 
delivered with cesarean section were with the main 
contributing factor- preterm fetus. Compare with the 
control group, these complications in pregnancy were 
rare. In the control group, the main indications was 
previous one or more cesarean section, disproportion, 
transverse lie or breech presentation of the fetus. Birth 
weight, average gestational age and Apgar score 
were similar in target and control group. The detection 
rates could be improved with appropriate intervention 
before complications arise.  
In term of fact, there are national 
recommendations for follow up of patients with low 
values of PAPP-A, we should attempt other countries. 
The main aim will be improving the perinatal outcome 
for mothers and the newborns. It is necessary to 
assess the cost-benefit if recommendations are going 
to be implemented in our circumstances. 
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